Encouraging Results From Nektar’s Product BEMPEG: NKTR-214 In Combination with the Checkpoint Inhibitor Nivolumab

Nektar Therapeutics
Nektar Therapeutics (NKTR) announced the publication of Phase 1 clinical data for its immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) + nivolumab, in Cancer Discovery -  a journal of the American Association for Cancer Research.

Previously published Phase 1 data in Cancer Discovery informed that BEMPEG administered as monotherapy . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.